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Abstract
Background: Diabetes and pre-diabetes are prevalent in acute coronary syndrome (ACS) and relate to adverse
outcomes. This study used HbA1c to screen for degrees of glucose intolerance amongst patients without known
diabetes presenting with ACS.
Methods: Over a 1-year period (June 2014–2015) consecutive patients admitted to a single centre cardiology unit
with an initial diagnosis of ACS without prior diabetes diagnosis were electronically referred to our diabetes team.
Patients were screened for the presence of diabetes by use of an initial HbA1c blood test on day 2 or 3 post
admission. If abnormal (≥42 mmol/mol; ≥6.0%), patients were invited for a repeat HbA1c at 2 weeks, and if an
intermediate result (42–47 mmol/mol; 6.0–6.4%), for an oral glucose tolerance test (OGTT) at 3 months. Patients
were diagnosed with Type 2 diabetes if the repeat HbA1c result was high (≥48 mmol/mol; ≥6.5%) or the OGTT at
3 months confirmed the diagnosis. Other data collected included baseline demographics, risk factors and any
history of cardiovascular disease. All patients with ACS were stratified according to the diagnosis and subsequent
management.
Results: We screened 399 patients in total. The mean age was 65 ± 14 years, 268 (67%) were men, 290 (73%) were
Caucasian, 95 (24%) were South Asian and 14 (4%) were Afro-Caribbean ethnicity. Of all patients, 57 (14.3%) were
diagnosed as pre-diabetes and 43 (10.8%) newly diagnosed diabetes. During the study 28 (7%) patients could not
be classified; 6 (1.5%) patients died during the study and 22 (5.5%) patients were missing either initial or repeat
HbA1c and were subsequently lost to follow up. Of the baseline variables assessed, there were significantly more
patients of South Asian ethnicity in the diabetes group compared to the normal group (42 vs 20%; p = 0.003). There
was no difference in detection rates in patients with more severe ACS requiring percutaneous or cardiac surgical
intervention.
Conclusions: The use of a simple HbA1c screening method in clinical practice can detect new onset diabetes in
approximately 1 in 10 high-risk post ACS patients.
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Background
It is estimated that more than 1 in 16 people in the UK
have diabetes mellitus; diagnosed or undiagnosed. Type
2 diabetes is recognised as a major cardiovascular risk
factor and its close relationship with cardiovascular
morbidity and mortality is well established [1]. Indeed,
cardiovascular disease has been accounted for 52% of
deaths in Type 2 diabetes [2]. Irrespective of the pres-
ence or absence of diagnosed diabetes, disturbances of
glucose metabolism are widely prevalent in patients
presenting with acute coronary syndrome (ACS). Even
in those patients without established Type 2 diabetes,
ACS patients with glucometabolic dysregulation have an
increased risk of mortality both in hospital and after
discharge [3–6].
Screening ACS patients on admission would enable
both early detection and management of glucose intoler-
ance and potentially improve patient outcomes. Most
recent guidelines by the European Society of Cardiology
in collaboration with European Association for the Study
of Diabetes have recommended that all ACS patients are
screened for Type 2 diabetes [7]. Current screening
methods using fasting plasma glucose (FPG) or the oral
glucose tolerance test (OGTT) have limitations in the
acute setting. In 2012 the World Health Organisation
(WHO) approved the use of HbA1c as the preferred
screening test in the diagnosis and targeted screening
for Type 2 diabetes [8]. The National Institute of Health
and Care Excellence (NICE) recommend that all ACS
patients with admission blood glucose concentrations
above 11.0 mmol/l should have FPG no earlier than day
4 after ACS onset or have an HbA1c test before dis-
charge [9]. A screening strategy using HbA1c as the pre-
ferred test would be pragmatic and improve early
detection and management of glucose intolerance in
acute cardiology care practice [10–12].
The aim of our study was to audit the effectiveness of
a simple screening programme based on HbA1c levels
alone to identify degrees of glucose intolerance amongst
non-diabetes patients presenting with ACS.
Methods
This prospective audit was conducted at a single-centre
over a 1-year period (June 2014–2015). Consecutive
patients admitted to a cardiology unit with an initial
diagnosis of ACS without prior diabetes diagnosis were
included. All patients had a random HbA1c on day 2 or
3 following admission and were simultaneously referred
to the diabetes team via Think Glucose, an electronic
referral system using iCM software, which was already
in place within our Trust. Our study to audit the effective-
ness of the established screening tool in clinical practice
was registered with Sandwell and West Birmingham NHS
Trust audit department (audit code 674).
Patients were managed according to a protocol (Fig. 1).
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Fig. 1 Study protocol including patient numbers for initial and repeat HbA1c test, and then oral glucose tolerance test (OGTT). *2 patients were
diagnosed with Type 2 diabetes as initial HbA1c levels≥ 99 mmol/mol with presence of symptoms; **5 patients attended OGTT at 3 months
despite missing their repeat HbA1c at 2 weeks
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Tosoh GA analyser using HPLC method (normal range
between 28 and 42 mmol/mol). Initial HbA1c were cate-
gorised as normal (<42 mmol/mol; <6.0%), intermediate
range (between 42 and 47 mmol/mol; 6.0% and 6.4%) or
high (≥48 mmol/mol; ≥6.5%) according to our NICE
screening guidance [9]. Patients with an intermediate or
high initial HbA1c were invited for a repeat HbA1c at
2 weeks as per American Diabetes Association guide-
lines to confirm diagnosis of Type 2 diabetes for those
with high levels [13]. Patients with a repeat HbA1c
within intermediate range were further categorised by an
OGTT at 3 months as previously recommended [10].
This was a standardised 75-g OGTT, performed in the
morning, after a 12-h overnight fast, and results were
defined as normal, impaired or consistent with diabetes
diagnosis, according to the WHO 1998 definitions [14].
Any abnormal test results were acted upon.
Data collected included baseline demographics of
age, sex, ethnicity and smoking status. Risk factors for
cardiovascular disease were also collected including
background of hypercholesterolaemia, hypertension,
peripheral vascular disease, cerebrovascular disease,
myocardial infarction, and any previous percutaneous
coronary intervention (PCI) or coronary artery bypass
graft (CABG). Other outcome data collected included
high sensitivity cardiac troponin T, which was mea-
sured on admission and at least 12 h after the pri-
mary clinical event and admission creatinine level.
The final ACS diagnosis on hospital discharge was re-
corded as ST-elevation myocardial infarction (STEMI),
non-ST elevation MI (NSTEMI), unstable angina, or not
ACS if investigations excluded the initial diagnosis. Subse-
quent management was recorded and included medical
therapy, percutaneous coronary intervention, and referral
for urgent coronary artery bypass graft. Inpatient mortality
was recorded, as were the data of those patients who did
not return for follow up testing.
Statistical analysis
Results are expressed as mean (SD) for continuous vari-
ables and as a percentage for categorical variables. A paired
t-test was used to compare initial and repeat HbA1c. The
baseline characteristics and outcomes of patients diagnosed
as normal, pre-diabetes and diabetes were compared using
Kruskal-Wallis (KW) for continuous variables and Fisher’s
exact test (FET) for categorical variables. Where the
comparison of the three groups was significant (p < 0.05),
pairwise comparisons were performed. Pairwise compari-
sons for KW were adjusted for multiple comparisons; those
for FET were not, therefore pairwise comparisons for FET
were treated as significant only if p < 0.0167. Statistical
analysis was performed using SPSS Statistics for Windows,
Version 22.0. Armonk, NY: IBM Corp.
Results
Initial HbA1c
Of the 399 patients in our study, results of initial HbA1c
were normal in 248 (62.2%) patients. Results were inter-
mediate in 120 (30.1%) patients and high in 24 (6%)
patients. Of those patients with an initial high HbA1c, 2
patients had HbA1c levels of 99 and 127 and were subse-
quently diagnosed with Type 2 diabetes due to the mark-
edly elevated level and the presence of symptoms. There
were 7 (1.8%) patients that did not have an initial HbA1c;
1 (0.3%) patient died following referral and 6 (1.5%)
patients were initially referred by the cardiology team
without HbA1c measurements and were subsequently
lost to follow up.
Repeat HbA1c
Of the 142 patients due for repeat HbA1c at 2 weeks,
results of the repeat HbA1c were normal in 23 (16.2%)
patients, intermediate in 57 (40.1%) patients, and diag-
nosed Type 2 diabetes in 36 (25.4%) patients. There
were 26 (18.3%) patients that did not have a repeat test
of which; 5 (3.5%) patients died and 21 (14.8%) patients
did not attend the follow up HbA1c. The difference in
HbA1c level between the initial and repeat test was
normally distributed (Fig. 2), with a mean (±SD) differ-
ence of 0.23 (±3.31) mmol/mol. There were no signifi-
cant differences between the initial HbA1c and the
repeat HbA1c levels (p = 0.506).
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Fig. 2 Histogram demonstrating the difference in HbA1c levels
between initial and repeat test (Repeat minus the initial HbA1c level)
in those initially identified as having HbA1c ≥ 42 mmol/mol
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OGTT at 3 months
There were 62 patients scheduled to attend an OGTT
at 3 months, this included 57 patients with a repeat
intermediate HbA1c and 5 patients who attended des-
pite missing their repeat HbA1c test. OGTT result
was normal in 28 (45.2%) patients, impaired in 12
(19.4%) patients, and diagnosed diabetes in 5 (8.1%)
patients. A total of 17 (27.4%) patients did not attend
the OGTT. Following OGTT, patients with an im-
paired or normal result, or those who were not tested
were all still classified as pre-diabetes due to the prior
intermediate repeat HbA1c result. Therefore a letter
was sent to their GP advising the patient to have an-
nual HbA1c levels or OGTT checked.
Final outcome
The end result of screening process diagnoses pre-
diabetes in 57 (14.3%) patients and Type 2 diabetes in
43 (10.8%) patients. During the study 28 (7%) patients
could not be classified; 6 (1.5%) patients died during
the study and 22 (5.5%) patients were missing either
initial or repeat HbA1c and were subsequently lost to
follow up.
Baseline characteristics and outcome
Of all the baseline characteristics studied in our pro-
spective study, the only characteristics that were signifi-
cantly different were ethnicity and sex (Table 1). On
univariate analysis, there appeared to be significantly
fewer men in the pre-diabetes group; however pairwise
comparisons between groups did not reach the level of
significance required (p < 0.0167). There were signifi-
cantly more patients who were South Asian in the Type
2 diabetes group compared to the normal group (42 vs
20%; p = 0.003). Significantly fewer patients who were
Caucasian had diabetes compared to the normal group
(53 vs 78%; p = 0.001). Interestingly there was no differ-
ence in the severity of ACS or management required
between patients with normal results, or those who were
diagnosed as pre-diabetes or Type 2 diabetes (Table 2).
Discussion
Our screening programme based solely on HbA1c blood
tests to detect diabetes and pre-diabetes in high-risk
ACS patients found approximately 1 in 10 patients with
incident diabetes. This concurs with the study by Arnold
et al. [15], that found among 2854 acute myocardial in-
farction patients without known diabetes on admission,
Table 1 Baseline characteristics of all patients and those in normal, pre-diabetes and Type 2 diabetes groups
All patients Normal Pre-diabetes Type 2 Diabetes Not classified P-value
(n = 399) (n = 271) (n = 57) (n = 43) (n = 28)
Initial HbA1c (mmol/mol) 39 (36–40)
b,c 44 (43–46) a 47 (46–50) a 44 (43–47) <0.001 KW
Repeat HbA1c (mmol/mol) 40 (38–41)
b,c 44 (43–46) a,c 50 (48–51) a,b <0.001 KW
Age (years) 65 (61–79) 64 (54–76) 70 (60–76) 64 (55–74) 76 (47–82) 0.276 KW
Sex (% Men) 268 (67%) 187 (69%) 31 (54%) 33 (77%) 17/28 (61%) 0.043 FET
Ethnicity:
Caucasian (%) 290 (73%) 212 (78%) c 36 (63%) 23 (53%) a 19 (68%) 0.002 FET
South Asian (%) 95 (24%) 53 (20%) c 17 (30%) 18 (42%) a 7 (25%)
Afro-Caribbean (%) 14 (4%) 6 (2%) 4 (7%) 2 (5%) 2 (7%)
Current Smoker (%) 84/386 (22%) 62/260 (24%) 10/56 (18%) 7/42 (17%) 5/28 (18%) 0.481 FET
Hypercholesterolaemia (%) 162/383 (42%) 103/257 (40%) 28/55 (51%) 20/43 (47%) 11/28 (39%) 0.295 FET
Cholesterol level (mmol/l) 4.6 (3.4–5.6) 4.4 (3.7–5.3) 4.7 (3.6–5.2) 4.4 (3.4–5.5) 3.9 (3.1–5.3) 0.974 KW
Hypertension (%) 200/387 (52%) 124/260 (48%) 34/56 (61%) 25/43 (58%) 17/28 (61%) 0.123 FET
PVD (%) 22/399 (6%) 12/267 (4%) 3/57 (5%) 3/43 (7%) 3/28 (11%) 0.674 FET
Previous stroke/TIA (%) 29/399 (7%) 19 (7%) 3 (5%) 4 (9%) 3 (11%) 0.673 FET
Cardiovascular disease:
Myocardial infarction (%) 94/396 (24%) 63/271 (23%) 13/56 (23%) 11/43 (26%) 7/27 (26%) 0.920 FET
Previous PCI (%) 72/399 (18%) 47 (17%) 13 (23%) 6 (14%) 6 (21%) 0.479 FET
Previous CABG (%) 26/399 (7%) 17 (6%) 5 (9%) 2 (5%) 2 (7%) 0.779 FET
KW kruskal-wallis, FET fisher’s exact test, TIA transient ischaemic attack, PVD peripheral vascular disease, CABG coronary artery bypass graft, PCI percutaneous
coronary intervention. The not classified group were excluded from the analysis. Where the comparison of the three groups is significant (p < 0.05), pairwise
comparisons were performed. Pairwise comparisons for KW are adjusted for multiple comparisons, those for FET were not, therefore pairwise comparisons for
FET were treated as significant only if p < 0.0167. Superscript letters (a-c) were used; (a) to mean significantly different from Normal group, (b) to mean significantly
different from Pre-diabetes group and (c) to mean significantly different from Type 2 diabetes group
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there were 287 patients (10%) that met criteria for Type
2 diabetes (defined by a core laboratory glycated haemo-
globin of ≥6.5%). They found that 2 of 3 patients with
newly diagnosed diabetes were unrecognized by treating
clinicians, receiving neither diabetes education, glucose-
lowering medications at discharge, nor documentation
of diabetes in the chart. Conversely, in our cohort, all
the newly diagnosed patients received education and
were seen in specialist clinic with regards to starting
glucose lowering medication.
In patients with established coronary artery disease, a
large study of 4004 patients has compared the screening
capacity of FPG, 2-h post load post plasma glucose
(2hPG), OGTT (FPG & 2hPG) and HbA1c [16]. In this
study 29% had undetected diabetes by the use of all
screening tests. Out of them, the proportion identified
by FPG was 75%, by 2hPG 40%, by HbA1c 17%, by FPG
+HbA1c 81%, and by OGTT FPG+ 2hPG 96%. Interest-
ingly, only 7% of diabetes were detected by all three
methods of FPG, 2hPG, and HbA1c. In patients with
ACS, previous studies investigating the prevalence of
undiagnosed Type 2 diabetes using OGTT during
admission (or following discharge) have found higher
absolute proportions compared to our study (20–30%)
[5, 17, 18]. The higher percentage of diagnosis is likely
due to the OGTT having previously shown to have
higher a sensitivity for detecting Type 2 diabetes than
HbA1c in patients with ACS [19, 20]. Therefore, the
results from our study in relying on HbA1c alone, may
be missing around 8% of patients with undetected dia-
betes. However, the alternative strategies of detecting
diabetes in ACS patients have their limitations in clinical
practice. Firstly, the FPG can be acutely elevated and
therefore can be unreliable in the first 2 days after a
myocardial infarction [20]. Secondly, the OGTT test can
also be affected by multiple factors, which include carbo-
hydrate diet and physical activity levels prior to the test
as well as the severity of myocardial damage and timing
of the test in relation to an index event [20]. The main
limitation of the OGTT however, as found in our pilot
study, is that it is resource intensive. The Euro Heart
Survey found that the recommended OGTT was per-
formed only in 56% of the patients [21]; this could be
explained by the ethical permits to perform an OGTT
not being issued in some countries, technical obstacles
experienced in the cardiology care setting for these not-
as-routine measures, and finally overt fasting hypergly-
caemia that was considered sufficient to establish the
diagnosis of diabetes.
The use of initial HbA1c test has several advantages over
FPG or an OGTT in the acute setting. Predominantly, as
the test can be performed in the non-fasting state and
reflects average glucose concentration over the preceding
2–3 months and is therefore not affected by stress-
induced changes in blood glucose levels. Indeed, we have
demonstrated that repeat levels within 2 weeks do not
show significant changes. HbA1c has also been shown to
independently predict glucose intolerance at 3 months in
patients admitted with ACS without known diabetes [odds
ratio (95% CI): 2.58 (1.17–6.09) p = 0.024], and correlates
with 2hPG and OGTT [16]. We repeated the HbA1c at
2 weeks, although this has been previously recommended
at 4–8 weeks mainly on logistical grounds, fully recognis-
ing that a one-off test would have perhaps been sufficient
for diagnostic purposes [10]. We found that repeat testing
at 2 weeks was feasible, practical and a reassuring test to
confirm the diagnosis and promptly inform patients of the
diagnosis of potential glucose abnormalities.
Table 2 Cardiovascular outcome in normal, pre-diabetes and Type 2 diabetes groups
Normal Pre-diabetes Type 2 Diabetes Not classified P-value
(n = 271) (n = 57) (n = 43) (n = 28)
Creatinine (micromol/l) 82 (70–101) 83 (71–97) 80 (68–101) 99 (79–136) 0.865 KW
Troponin T (ng/l) Initial 52 (20–242) 52 (22–138) 67 (15–244) 60 (35–1980) 0.892 KW
Repeat 158 (37–721) 83 (36–514) 113 (29–1167) 79 (33–3050) 0.551 KW
% Change 44 (1–312) 19 (0–273) 46 (1–238) 21 ((−2) − 145) 0.541 KW
ACS diagnosis STEMI 100 (37%) 15 (26%) 11 (26%) 9 (32%) 0.485 FET
NSTEMI 100 (37%) 25 (44%) 21 (49%) 9 (32%)
Unstable angina 29 (11%) 8 (14%) 6 (14%) 3 (11%)
Not ACS 42 (15%) 9 (16%) 5 (12%) 7 (25%)
Management Nil 39 (14%) 9 (16%) 5 (12%) 7 (25%) 0.753 FET
Medical 57 (21%) 16 (28%) 7 (16%) 5 (18%)
PCI 149 (55%) 26 (46%) 27 (63%) 14 (50%)
CABG 26 (10%) 6 (11%) 4 (9%) 2 (7%)
KW kruskal-wallis, FET fisher’s exact test, ACS acute coronary syndrome, STEMI ST elevation myocardial infarction, NSTEMI non-ST elevation myocardial infarction,
PCI percutaneous coronary intervention, CABG coronary artery bypass graft
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Given the association with elevated HbA1c and mor-
tality, Gholap et al. recommend performing an OGTT
at 4–8 weeks post-discharge in those with HbA1c be-
tween 42 and 47 mmol⁄mol (6.0 and 6.4%) for accurate
categorisation of glucose intolerance [10]. Performing
OGGT in patients with HbA1c <42 mmol/mol (<6.0%)
was not recommended, and this is supported by NICE
guidelines [9]. Gholap et al. made recommendations
that these patients should be followed up with annual
HbA1c measurements; however there is limited evi-
dence available for this at present. We felt that indefin-
ite annual HbA1c measurements of these individuals
may strain services, and wanted to emphasise annual
follow up in those patients who had abnormal HbA1c
and OGTT not meeting criteria for diabetes diagnosis.
Other than known diabetes, there were no other exclu-
sion criteria to the patients involved in our study. There
are limitations to the HbA1c test, which includes the in-
fluence of red cell survival; any condition that shortens
erythrocyte survival or decreases mean erythrocyte age
may falsely lower HbA1c test results regardless of the
assay method used [22]. Furthermore, we did not
exclude patients on the basis of chronic kidney disease
severity; however some studies have shown that al-
though the HbA1c test performs well in milder chronic
kidney disease, the accuracy of the test in patients with
severe nephropathy requires further investigation [23].
We found a significantly high proportion of dysgly-
caemia in the South Asian population. This finding
is in keeping with other studies demonstrating that
Asian Indians without prior diagnosed diabetes show
a high prevalence of hyperglycaemia following ACS
[24]. An important factor, which may be contributing
to this finding, is that HbA1c concentrations have
been shown to be higher in some ethnic groups
(Afro-Caribbean, Hispanic, Asian) compared to Cau-
casian patients with similar plasma glucose levels
[25]. Our study also found that the incidence of pre-
diabetes and Type 2 diabetes did not differ between pa-
tients with differing severity of ACS. This is supported by
previous studies that have shown patients with stable
and unstable coronary artery disease [20], as well as
patients with cerebro- and peripheral vascular disease
have about the same proportion of previously unrec-
ognised diabetes [26]. This further supports that this
screening programme should be utilised for all sus-
pected ACS patients, regardless of severity. Snir et al.,
found that in a multicentre observational study of
1743 patients, only 41% of diabetes patients admitted
with ACS have HbA1c measured in hospital [27].
There was a great variation in practice in different
centres from 7.7 to 87.6%; those patients who were
tested were more likely to have STEMI and referred
for cardiac catheterisation.
Limitations
This is a real life prospective study utilising a simple
screening programme in ACS patients without prior
diabetes diagnosis, involving patients of all ages and
associated comorbidities seen in day-to-day clinical prac-
tice. We accept that including more comorbid patients
may have increased the prevalence of glucometabolic
disturbances in our study, though we did not find any
significant differences in pre-diabetes and diabetes in pa-
tients with other cardiovascular comorbidities including
hypertension, cerebro- and peripheral vascular disease.
Data is incomplete for some patients, as they were lost
to follow up. However, only a minority of patients (5.5%)
did not receive an outcome. Our study showed a larger
number of patients did not attend their OGTT; approxi-
mately 1 in 3 patients did not attend follow up appoint-
ment at 3 months. These patients were already recognised
as high risk following their initial HbA1c result and were
recommended annual follow up for this reason. Further-
more, we acknowledge that not all patients presenting
with ACS within the time period would have been tested
and referred, as we only captured data of those patients
who were referred via our Think Glucose iCM referral
system. Our cardiology ward admits approximately 600
patients per year with suspected ACS; therefore we have
been successful in screening 2 in 3 patients admitted, with
some of the remaining patients not be suitable for screen-
ing because of pre-existing diabetes diagnosis. Finally, we
have used HbA1c as a screening tool in a relatively acute
post ACS situation where its validity has not been robustly
tested but we feel that the practical difficulties and limita-
tions FPG and OGTT offers, HbA1c is still a worthwhile,
simple and practical screening option.
Conclusions
We have screened our post ACS patients with a simple
and practical random HbA1c blood test. This method has
detected approximately 1 in 7 patients with pre-diabetes
and 1 in 10 with diabetes in high-risk post ACS patients,
who would otherwise have been missed, with potential im-
plications. Patients of South Asian ethnicity presenting
with ACS are at highest risk of developing Type 2 diabetes.
All this fits in with the global drive towards screening and
detecting new onset Type 2 diabetes in high-risk popula-
tions. However, further prospective studies are needed to
address the role of HbA1c in strategies to accurately screen
for every new patient with diabetes post ACS.
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